Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1

研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力

• 批准号: 428988
• 负责人: Misquitta Naomi S
• 金额: $ 1.27万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428988&lang=en
• 关键词: Amp-Activated Protein Kinase; Combinatorial Therapeutics; Exercise Training; Muscular Dystrophy; Myotonic Dystrophy Type 1; Pharmacological Treatment Strategies; Skeletal Muscle

"Myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy in Canada and worldwide, is a hereditary neuromuscular disorder that results in skeletal muscle weakness, wasting and myotonia. Due to its progressive nature, individ

“强直性肌营养不良1型（DM1），在加拿大和世界范围内最常见的成人发病型肌营养不良症，是一种遗传性神经肌肉疾病，导致骨骼肌无力，消瘦和肌强直。由于其渐进性，